Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Researchers at the troubled Biogen are touting the latest safety update on a Phase III MS drug now under review at the FDA. Designed as a milder drug than its MS star Tecfidera, the company reported that there was a discontinuation rate of 0.7% over one year of treatment using diroximel fumarate, an oral therapy which they believe will help position this on the market in 2020.
Biogen partnered with Alkermes to get this drug, which is unlikely to do a whole lot in terms of reforming the big biotech’s tarnished R&D rep after the late-stage failure of aducanumab. Alkermes — which has had plenty of its own R&D problems with the me-better approach — dubbed this one ALKS 8700, which they plan to sell as Vumerity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.